<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6022">
  <stage>Registered</stage>
  <submitdate>31/05/2016</submitdate>
  <approvaldate>31/05/2016</approvaldate>
  <nctid>NCT02869087</nctid>
  <trial_identification>
    <studytitle>The DESappear Study: Drug Eluting Scaffold</studytitle>
    <scientifictitle>DESappear Study: Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization</scientifictitle>
    <utrn />
    <trialacronym>DESappear</trialacronym>
    <secondaryid>ELX CL 1501</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Vascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Akesys Prava Scaffold

Experimental: Single Group - Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold


Treatment: devices: Akesys Prava Scaffold
Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Freedom from composite of perioperative death &lt; 30 days and freedom from major adverse limb events (MALE) defined as the occurrence of major amputation, thrombectomy, thrombolysis or major open surgical revascularization - Primary Safety Endpoint</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Patency defined as the freedom from restenosis (&gt;50% diameter reduction defined by Duplex Ultrasound) or clinically driven target lesion revascularization through 6 months - Primary Effectiveness Endpoint</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from composite of perioperative death within 30 days and freedom from major adverse limb events (MALE) defined as the occurrence of major amputation, thrombectomy, thrombolysis or major open surgical revascularization. - Secondary Safety endpoint</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from the composite of target lesion (TL) occlusion, reintervention or restenosis defined as a &gt;50% diameter reduction in the target lesion, as confirmed by Duplex Ultrasound or angiography - Secondary Effectiveness Endpoint</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical Success defined as the successful delivery and deployment of the device assessed by angiography at the conclusion of the procedure - The assessment will be made and evaluated at the conclusion of the index procedure</outcome>
      <timepoint>Post Procedure- Procedure may take up to 2 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical Success defined as no implantation of metallic stent assessed by angiography at the conclusion of the procedure - the assessment will be made and evaluated at the conclusion of the Index procedure</outcome>
      <timepoint>Post Procedure, procedure may take up to 2 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical Success defined as &lt; 30%residual stenosis after successful implantation of the scaffold assessed by angiography at the conclusion of the procedure - The assessment will be made and evaluated at the conclusion of the index procedure</outcome>
      <timepoint>Post Procedure, procedure may take up to 2 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major target extremity amputation</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minor target extremity amputation</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold Thrombosis</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion binary restenosis by duplex ultrasound Peak Systolic Velocity ratio (PSVR&gt;2.4)</outcome>
      <timepoint>1 month, 6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically driven target lesion restenosis defined as any intervention due to worsening symptoms, a fall in ABI or TL restenosis as determined by duplex ultrasound</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target extremity revascularisation</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary patency of the target lesion</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary assisted patency of the target lesion</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary patency of the target lesion</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rutherford Becker clinical category</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ankle Brachial Index in the target extremity</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Walking Capacity as demonstrated by the Walking Impairment Questionnaire</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life measures using VASCUQoL- disease specific</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duplex ultrasound derived Peak Velocity (PSV) at the target lesion</outcome>
      <timepoint>1 month,6 months,12 months, 24 months, 36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clinical inclusion criteria:

          1. Subject is =18 years of age.

          2. Subject has been informed of the nature of the study, agrees to its provisions, is
             able to provide informed consent, and agrees to undergo all protocol-required follow
             up examinations and requirements.

          3. Subject's life expectancy is at least 1 year.

          4. Subject is diagnosed as having symptomatic claudication (Rutherford-Becker Clinical
             Category 2-4).

          5. For females of childbearing potential, a negative pregnancy test within 14 days before
             index procedure is required

          6. Subject is able to take a P2Y12 receptor antagonist (e.g. clopidogrel, ticagrelor,
             prasugrel or ticagrelor) and acetylsalicylic acid (aspirin).

        Angiographic inclusion criteria:

          1. A single, de novo native disease segment of the SFA

          2. Proximal margin of target lesion is =1 cm distal to the common femoral artery
             bifurcation; distal margin of target lesion is within the SFA.

          3. Vessel diameter from =5.0 mm to =6.0 mm evaluated by on-line quantitative vascular
             angiography (QVA) after pre-dilatation per core laboratory guidelines.

          4. Target lesion diameter reduction =50%

          5. Target lesion length =53 mm

          6. Patent inflow artery free from significant lesion (=50% diameter reduction;

          7. Patent distal popliteal artery free from significant lesion (=50%) with angiographic
             demonstration of at least one fully patent distal outflow artery (anterior tibial,
             posterior tibial, or peroneal) to its terminus.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinical exclusion criteria:

          1. Previous bypass surgery or stenting at the TL;

          2. Percutaneous or open surgical revascularization of the contralateral iliac or
             infrainguinal arteries =30 days prior to the planned index procedure. Iliac artery
             lesions may be treated during the index procedure if necessary for approach to the TL;

          3. Failure to successfully cross the target lesion with a guide wire;

          4. Subject has a known abdominal aortic aneurysm &gt;4 cm in diameter, a known iliac artery
             aneurysm &gt;3 cm in diameter, or history of open surgical abdominal aortic or iliac
             revascularization.

          5. Lesion within or adjacent to an aneurysm or presence of a popliteal aneurysm;

          6. Subject is receiving immunosuppression therapy and has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus);

          7. Acute limb ischemia;

          8. History of a bleeding diathesis;

          9. History of a hypercoagulability syndrome;

         10. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3; a WBC &lt;3,000 cells/mm3; or
             hemoglobin &lt;10.0 g/dL;

         11. Acute or chronic renal dysfunction (creatinine &gt;2.5 mg/dl or &gt;176 Âµmol/L), or on
             chronic hemodialysis;

         12. Severe liver impairment as defined by total bilirubin =3 mg/dl or two times increase
             over the normal level of SGOT/AST or SGPT/ALT;

         13. Known allergies to the following: aspirin, clopidogrel, prasugrel, ticagrelor, or
             heparin, contrast agent (that cannot be adequately premedicated), or drugs similar to
             sirolimus (i.e. tacrolimus, everolimus, zotarolimus) or other macrolides;

         14. Subject requires planned procedure within 30 days that would necessitate the
             discontinuation of clopidogrel, prasugrel, or ticagrelor;

         15. Subject is on chronic Coumadin therapy

         16. Subject has had or is planned to have treatment with DES or drug coated balloon (DCB)
             within 90 days pre- or post-index procedure;

         17. Subject is non-ambulatory;

         18. Subject has undergone percutaneous intervention of the coronary, carotid, or arterial
             bed exclusive of the &lt;30 days prior to the planned index procedure.

         19. Subject has received, or is on the waiting list for, an organ transplant;

         20. Subject had a myocardial infarction (MI) within the previous 30 days prior to the
             planned index procedure;

         21. Subject has had a stroke within the previous 30 days of the planned index procedure
             and/or has deficits from a prior stroke that limit the subject's ability to walk;

         22. Subject has unstable angina defined as rest angina with ECG changes;

         23. Subject has a groin infection, or an acute systemic infection that has not been
             treated successfully or is currently under treatment;

         24. Subject has acute thrombophlebitis (superficial or deep) in either extremity;

         25. Subject has other medical conditions (e.g., cancer, congestive heart failure or
             substance abuse) that may cause the subject to be non-compliant with protocol
             requirements or confound data interpretation;

         26. Subject is currently participating or wanting to participate in a clinical trial
             following 6 months after the index procedure in an investigational drug, biologic, or
             device study that has not completed the primary endpoint or that clinically interferes
             with the current study endpoints. (Note: Trials requiring extended follow-up for
             products that were investigational, but have since become commercially available, are
             not considered investigational trials);

         27. Subject is unable to understand or unwilling to cooperate with study procedures;

         28. Subject has prior minor or major amputation of either lower extremity;

         29. Subject is part of a vulnerable population who, in the judgment of the investigator,
             is unable to give informed consent for reasons of incapacity, immaturity, adverse
             personal circumstances or lack of autonomy;

         30. Pre-operative plan for additional treatment of the target lesion at the time of the
             study procedure with alternative therapy such as drug-eluting stent (DES) and
             scaffold, laser, atherectomy, cryoplasty, cutting balloon, drug-eluting balloon, or
             brachytherapy (vessel preparation with uncoated balloon angioplasty is allowed);
             31Plan for cardiovascular surgical or interventional procedure =30 days after the
             study procedure including planned treatment of the contralateral lower extremity.

        Angiographic exclusion criteria:

          1. Target extremity has an angiographically significant (&gt;50% diameter reduction) lesion
             located in the target vessel distal to the target lesion;

          2. Thrombus in the target vessel;

          3. Stenosis (&gt;50%) or occlusion of an ipsilateral inflow artery;

          4. Angiographic evidence of thromboembolism or atheroembolism from treatment of an
             ipsilateral iliac lesion, or from crossing or pre-dilating the target lesion;

          5. Target lesion has calcification with either of the following characteristics:

               -  Circumferential orientation, or

               -  Thickness &gt;2 mm (radially) within the wall of the target lesion.

          6. Failure to achieve less than 30% residual stenosis after balloon predilation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Tienen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Elixir Medical Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Syntactx</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Massachusetts General Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Genae associates</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to prospectively collect information to evaluate the safety and
      performance of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system
      for the treatment of symptomatic primary atherosclerotic stenoses and occlusions of the
      superficial femoral artery (SFA).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02869087</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marc Bosiers, Doctor</name>
      <address>AZ Sint-Blasius Dendermonde</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Stephanie Simpson-Plaumann, Mrs</name>
      <address />
      <phone>+33 658473696</phone>
      <fax />
      <email>ssplaumann@elixirmedical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>